Mergers & AcquisitionsLupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Lupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Read Post »
Clinical TrialsBridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... BridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... Read Post »
Health TidingsUltragenyx UX111 Nears Decision After FDA Acceptance Ultragenyx UX111 Nears Decision After FDA Acceptance Read Post »
Clinical TrialsImfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Imfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Read Post »
Clinical TrialsInnovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Innovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Read Post »
Clinical TrialsNovo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Novo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Read Post »
Health Tidings Mergers & AcquisitionsZai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Zai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Read Post »
Clinical TrialsInnovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Innovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Read Post »
Health TidingsRay Therapeutics Secures RMAT for RTx-015 in RP Ray Therapeutics Secures RMAT for RTx-015 in RP Read Post »
Health TidingsCogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Cogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Read Post »
Health TidingsFDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... FDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... Read Post »
Clinical TrialsPepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study PepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study Read Post »
New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Lilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Read Post »
Health TidingsAgios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Agios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Read Post »
Clinical TrialsOcugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Ocugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Read Post »
Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health BioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health Read Post »
Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Axsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Read Post »
GenericsFrom Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... From Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... Read Post »
Health TidingsScholar Rock Resubmits Apitegromab BLA to FDA Scholar Rock Resubmits Apitegromab BLA to FDA Read Post »
Drugs Safety AlertFDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) FDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) Read Post »
Clinical TrialsAstra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Astra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Read Post »
Health Tidings Mergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Biogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Read Post »
Health Tidings Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Galapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Read Post »
Clinical TrialsConnect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Connect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Read Post »
Clinical TrialsUnited Therapeutics’ Tyvaso Surpasses TETON-2 with Strong TETON-1 IPF Res... United Therapeutics’ Tyvaso Surpasses TETON-2 with Strong TETON-1 IPF Res... Read Post »
Clinical TrialsMerck’s Oral PCSK9 Candidate Enlicitide Cuts LDL-C by 64.6% in Phase 3 Ad... Merck’s Oral PCSK9 Candidate Enlicitide Cuts LDL-C by 64.6% in Phase 3 Ad... Read Post »
Clinical TrialsTanabe’s Dersimelagon Improves Sunlight Tolerance in Phase 3 Study in Rar... Tanabe’s Dersimelagon Improves Sunlight Tolerance in Phase 3 Study in Rar... Read Post »
Mergers & AcquisitionsLilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep ... Lilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep ... Read Post »
Clinical TrialsWith 3-Dose Regimen, Viridian’s Elegrobart Shows Breakthrough Potential i... With 3-Dose Regimen, Viridian’s Elegrobart Shows Breakthrough Potential i... Read Post »
Health TidingsAquestive Aligns with FDA on Anaphylm NDA Resubmission, Aim Q3 2026 Filing Aquestive Aligns with FDA on Anaphylm NDA Resubmission, Aim Q3 2026 Filing Read Post »
Health TidingsEU Expands Kerendia Label: Bayer’s Finerenone Approved for Broader Heart ... EU Expands Kerendia Label: Bayer’s Finerenone Approved for Broader Heart ... Read Post »
Clinical TrialsConnect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Connect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Read Post »
Clinical TrialsBeyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Beyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Read Post »
Health Tidings Mergers & AcquisitionsAfter NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico After NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico Read Post »
Clinical TrialsBMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... BMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... Read Post »
Health TidingsFDA Clears IND for Sialic Acid Prodrug UX016 in GNEM FDA Clears IND for Sialic Acid Prodrug UX016 in GNEM Read Post »
Health TidingsAmgen’s Repatha Lowers First CV Risk in High-Risk Patients Amgen’s Repatha Lowers First CV Risk in High-Risk Patients Read Post »
New Drug ApprovalBiogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Biogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Read Post »
Clinical TrialsBiogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Biogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Read Post »
ResearchCorcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Corcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Read Post »
Health TidingsSanofi’s Sarclisa SC Gets CHMP Nod with OBI Option Sanofi’s Sarclisa SC Gets CHMP Nod with OBI Option Read Post »
Health TidingsAfter FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in Psoria... After FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in Psoria... Read Post »
Health TidingsPriovant’s Brepocitinib Gains Priority Review After Phase 3 Success Priovant’s Brepocitinib Gains Priority Review After Phase 3 Success Read Post »
Health TidingsNovartis’ Fabhalta Cuts Kidney Function Decline by 50% in Phase 3 Novartis’ Fabhalta Cuts Kidney Function Decline by 50% in Phase 3 Read Post »
Health TidingsBIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control i... BIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control i... Read Post »
Clinical TrialsTakeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Read Post »
Clinical TrialsIncyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Incyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Read Post »
Clinical TrialsTaltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Taltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Read Post »
Clinical TrialsLilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Lilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Read Post »
Clinical TrialsSanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Sanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Read Post »
